Key Performance
More- Earnings Score: 52
- Momentum Score: 82
- True Yield: N/A
- Financial Health Score: 89
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
DelveInsight's report analyzes the IgE receptor antagonists pipeline with 12+ companies developing therapies for allergic diseases. ADL-018 by Amneal/Kashiv leads in registration stage, while LP-003 by LongBio shows superior Phase II efficacy compared to omalizumab. The market is becoming increasingly competitive with focus on clinical differentiation and speed to market, particularly in China.
06/04/2026, 1:00 PM • GlobeNewswire
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opportunity. The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
04/22/2026, 7:15 AM • Benzinga
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol on April 14, 2026. These are the company's first two metered-dose inhalation (MDI) product launches, marking entry into the complex inhalation category. The products target large markets worth approximately $1.5 billion and $321 million respectively, manufactured at Amneal's dedicated inhalation facility in Ireland.
04/14/2026, 8:00 AM • GlobeNewswire
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.
02/13/2026, 11:26 AM • Benzinga
S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.
01/27/2026, 6:02 PM • Benzinga
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
Amneal Pharmaceuticals reported promising interim results from its ELEVATE-PD study for CREXONT, a new extended-release Parkinson's disease treatment. The study showed significant improvements in patient 'Good On' time, reduced 'Off' time, and enhanced motor symptom control across 55 patients.
12/05/2025, 8:00 AM • GlobeNewswire
Amneal to Participate in Upcoming Investor Conferences
Amneal Pharmaceuticals executives Chirag Patel and Tasos Konidaris will participate in two upcoming healthcare investor conferences in December 2025 and January 2026, presenting the company's strategic outlook.
12/02/2025, 8:00 AM • GlobeNewswire
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.
10/09/2025, 9:31 AM • Benzinga
3 Lesser-Known Healthcare Names With Major Upside in Store
The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.
10/02/2025, 9:06 AM • Investing
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Amneal Pharmaceuticals submitted a Biologics License Application (BLA) to the FDA for a biosimilar to XOLAIR, developed with Kashiv BioSciences. The potential entry targets the $4+ billion U.S. market for omalizumab, with expected milestone charges and future growth opportunities.
09/26/2025, 8:00 AM • GlobeNewswire
Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging
The global ophthalmic packaging market is expected to grow from $12.38 billion in 2026 to $23.65 billion by 2034, driven by increasing eye diseases, aging populations, and technological advancements in packaging solutions.
09/12/2025, 4:00 AM • GlobeNewswire
Global binge eating disorders market is growing due to advances in diagnostics, digital health technologies, and personalized treatments, with North America leading market expansion despite challenges like social stigma and high therapy costs.
08/27/2025, 8:00 AM • GlobeNewswire
Thérapeutique Knight has submitted a new drug submission for CREXONT®, a novel oral carbidopa/levodopa formulation for Parkinson's disease treatment, to Health Canada. The drug aims to provide improved therapeutic options with extended-release capsules and has demonstrated promising clinical trial results.
07/18/2025, 7:00 AM • GlobeNewswire
Knight Therapeutics filed a New Drug Submission for CREXONT®, an innovative extended-release Parkinson's disease treatment, with Health Canada. The drug aims to improve patient treatment by offering longer drug absorption and fewer daily doses.
07/18/2025, 7:00 AM • GlobeNewswire
Amneal Pharmaceuticals announced positive results from a clinical trial evaluating a biosimilar candidate to XOLAIR(R) (omalizumab), developed by Kashiv BioSciences. The study met its primary and secondary endpoints, and Amneal holds exclusive U.S. commercialization rights for the product, which is expected to be filed with the FDA in Q4 2025.
06/25/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.